Edgar Filing: ARRAY BIOPHARMA INC - Form 8-K

ARRAY BIOPHARMA INC Form 8-K April 08, 2005

QuickLinks -- Click here to rapidly navigate through this document

# SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, DC 20549** 

## FORM 8-K

### **CURRENT REPORT**

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 7, 2005

# Array BioPharma Inc.

(Exact name of registrant as specified in its charter)

Delaware000-3197984-1460811(State or Other Jurisdiction<br/>of Incorporation)(Commission<br/>File Number)(IRS Employer<br/>Identification No.)

**3200 Walnut Street, Boulder, Colorado** (Address of Principal Executive Offices)

80301

(Zip Code)

Registrant's telephone number, including area code: (303) 381-6600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### ITEM 8.01. OTHER EVENTS

0

On April 7, 2005, Array BioPharma Inc. issued a press release announcing the expansion of a collaboration agreement with Genentech, Inc. to develop small molecule drugs against an additional protein target in the field of oncology, the full text of which is attached hereto as Exhibit 99.1.

## Edgar Filing: ARRAY BIOPHARMA INC - Form 8-K

### ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

99.1

Press release dated April 7, 2005 entitled "Array BioPharma and Genentech Expand Oncology Collaboration."

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARRAY BIOPHARMA INC.

Date: April 7, 2005 By: /s/ ROBERT E. CONWAY

Robert E. Conway Chief Executive Officer

#### EXHIBIT INDEX

#### Exhibit No.

99.1 Press release dated April 7, 2005 entitled "Array BioPharma and Genentech Expand Oncology Collaboration."

QuickLinks

ITEM 8.01. OTHER EVENTS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
SIGNATURES
EXHIBIT INDEX